Beam Therapeutics (BEAM) Stock Statistics & Valuation Metrics

Beam Therapeutics has a market cap or net worth of $2.77B. The enterprise value is $2.81B.

Beam Therapeutics has 101,856,250 shares outstanding. The number of shares has decreased by -2.65% in one year.

Beam Therapeutics’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -27.43%.

The current PE Ratio of Beam Therapeutics is ―. Beam Therapeutics’s PEG ratio is 0.42.

In the last 12 months, Beam Therapeutics had revenue of 139.74M and earned -79.99M in profits. Earnings per share was -0.81.

In the last 12 months, operating cash flow was -345.10M and capital expenditures -14.95M, giving a free cash flow of -360.05M billion.

Beam Therapeutics pays an annual dividend of $0.225, resulting in a dividend yield of ―

Beam Therapeutics upcoming earnings date is May 12, 2026, Before Open (Confirmed).

Beam Therapeutics as a current ratio of 13.09, with Debt / Equity ratio of 23.73%

In the past 12 months, Beam Therapeutics has paid 0.00 in taxes.

Beam Therapeutics EV to EBITDA ratio is -91.59, with an EV/FCF ratio of -7.61.

Beam Therapeutics has $1.25B in cash and marketable securities with $293.88M in debt, giving a net cash position of $951.33M billion.

Gross margin is -126.14%, with operating margin of -274.57%, and net profit margin of -57.24%.

The average price target for Beam Therapeutics is $48.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy